Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock

by · The Cerbat Gem

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $39.15, for a total transaction of $195,750.00. Following the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $507,579.75. The trade was a 27.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amy Bachrodt also recently made the following trade(s):

  • On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.58, for a total value of $405,800.00.
  • On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.08, for a total transaction of $200,400.00.

Maze Therapeutics Trading Down 0.7%

Maze Therapeutics stock traded down $0.26 during trading hours on Tuesday, reaching $38.37. 241,160 shares of the company were exchanged, compared to its average volume of 330,787. Maze Therapeutics, Inc. has a 12 month low of $6.71 and a 12 month high of $43.29. The stock has a 50-day moving average of $37.15 and a 200 day moving average of $25.26. The firm has a market cap of $1.85 billion and a price-to-earnings ratio of -1.84.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Analyst Ratings Changes

MAZE has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. HC Wainwright lifted their target price on shares of Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, December 3rd. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Guggenheim restated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Friday, December 19th. Finally, Wells Fargo & Company started coverage on Maze Therapeutics in a report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $43.38.

Read Our Latest Report on MAZE

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its holdings in Maze Therapeutics by 80.7% in the third quarter. JPMorgan Chase & Co. now owns 7,890 shares of the company’s stock valued at $205,000 after purchasing an additional 3,524 shares during the last quarter. Woodline Partners LP boosted its stake in Maze Therapeutics by 10.0% during the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after acquiring an additional 94,529 shares during the last quarter. XTX Topco Ltd acquired a new position in Maze Therapeutics during the third quarter valued at approximately $697,000. Susquehanna International Group LLP increased its stake in Maze Therapeutics by 53.0% in the third quarter. Susquehanna International Group LLP now owns 16,165 shares of the company’s stock valued at $419,000 after purchasing an additional 5,598 shares in the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in shares of Maze Therapeutics in the 3rd quarter valued at $5,186,000.

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

See Also